177 related articles for article (PubMed ID: 34453757)
1. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Song AB; Goodarzi K; Karp Leaf R; Kuter DJ; Al-Samkari H
Am J Hematol; 2021 Dec; 96(12):1563-1568. PubMed ID: 34453757
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
4. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
Al-Samkari H; Parnes AD; Goodarzi K; Weitzman JI; Connors JM; Kuter DJ
Haematologica; 2021 Apr; 106(4):1148-1157. PubMed ID: 32499239
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim.
Kuter DJ
Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
[TBL] [Abstract][Full Text] [Related]
7. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
10. Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Hematol; 2023 May; 16(5):365-375. PubMed ID: 37039010
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.
Demeter J; Istenes I; Fodor A; Paksi M; Dombi P; Valasinyószki E; Csomor J; Matolcsy A; Nagy ZG
Pathol Oncol Res; 2011 Mar; 17(1):141-3. PubMed ID: 20628840
[TBL] [Abstract][Full Text] [Related]
12. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Haematologica; 2018 Apr; 103(4):e169-e172. PubMed ID: 29242295
[No Abstract] [Full Text] [Related]
13. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
14. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim in the management of the thrombocytopenic surgical patient.
Marshall AL; Goodarzi K; Kuter DJ
Transfusion; 2015 Oct; 55(10):2505-10. PubMed ID: 26033367
[TBL] [Abstract][Full Text] [Related]
16. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.
Al-Samkari H; Soff GA
Expert Rev Hematol; 2021 May; 14(5):437-448. PubMed ID: 33926362
[No Abstract] [Full Text] [Related]
17. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
18. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
[TBL] [Abstract][Full Text] [Related]
20. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia.
Miao J; Leblebjian H; Scullion B; Parnes A
Am J Hematol; 2018 Aug; 93(4):E86-E88. PubMed ID: 29274130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
